1 follower
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.
Industries
Headquarters
Stage
Employees
Links
Charles McDermott
8 members
6 members
4 members
3 members
Coherus BioSciences
5 followers
BioMarin Pharmaceutical
20 followers
Adaptive Biotechnologies
11 followers
Eikon Therapeutics
Dragonfly Therapeutics
Discover companies